Results 211 to 220 of about 124,738 (260)

Specific HIV-1 Reverse Transcriptase Inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry, 1992
Zeger Debyser, R Pauwels, K Andries
exaly   +3 more sources

Hepatotoxicity of Nucleoside Reverse Transcriptase Inhibitors

Seminars in Liver Disease, 2003
Hepatotoxicity is an adverse effect of all available classes of antiretrovirals, including nucleoside reverse transcriptase inhibitors (NRTI). A syndrome of hepatic steatosis and lactic acidosis has been recognized as a rare, potentially fatal complication since the advent of NRTI monotherapy in the early 1990s.
Valentina, Montessori, Marianne, Harris, Julio S G, Montaner   +2 more
openaire   +2 more sources

Inhibitors of HIV‐1 Reverse Transcriptase

2008
Publisher Summary With the identification of human immunodeficiency virus (HIV)‐1 as the infectious agent leading to acquired immune deficiency syndrome (AIDS), the viral reverse transcriptase (RT) has been a primary focus for drug discovery and development. Currently, two classes of RT inhibitors are used clinically. Nucleoside reverse transcriptase
Tatiana, Ilina, Michael A, Parniak
openaire   +2 more sources

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children

Clinical Drug Investigation, 2007
By the end of 2006, approximately 2.3 million children worldwide were living with HIV infection, representing about 15% of all HIV-infected individuals but only 5-7% of the total population of treated patients worldwide. Despite a general increase in the use of antiretroviral therapy (ART) in resource-limited settings, appropriate care and ART remain ...
GIAQUINTO, CARLO, RAMPON O, PENAZZATO M, FREGONESE F, DE ROSSI, ANITA, D'ELIA R.   +5 more
openaire   +3 more sources

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial

AIDS, 2009
The use of nonnucleoside reverse transcriptase inhibitor (NNRTI) + protease inhibitor regimen for the treatment of antiretroviral-naive patients was less successful than classical nucleoside reverse transcriptase inhibitor (NRTI) based regimen and associated with more resistance for protease inhibitors and NNRTIs. The selection for NNRTI resistance was
Cathia, Soulié, Lambert, Assoumou, Jade, Ghosn, Claudine, Duvivier, Gilles, Peytavin, Zaina, Ait-Arkoub, Jean-Michel, Molina, Dominique, Costagliola, Christine, Katlama, Vincent, Calvez, Anne-Geneviève, Marcelin   +10 more
openaire   +2 more sources

New Reverse Transcriptase Inhibitors

1999
Reverse transcriptase inhibitors used in the treatment of HIV-1 infection include the nucleoside analogues zidovudine, didanosine, zalcitabine, lamivudine and stavudine. More recently a number of other classes of reverse transcriptase inhibitors have been discovered, and are in various phases of clinical trial. This chapter will focus on the nucleoside
openaire   +2 more sources

HIV Inhibitors Targeted at the Reverse Transcriptase

AIDS Research and Human Retroviruses, 1992
HIV inhibitors targeted at the virus-associated reverse transcriptase (RT) can be divided into two groups, depending on whether they are targeted at the substrate or nonsubstrate binding site. To the first group belong the 2′,3′-dideoxynucleosides (i.e., DDC, DDI), 3′-azido-2′,3′-dideoxynucleosides (i.e., AZT), 3′-fluoro-2′,3 ...
openaire   +2 more sources

Coumarins as Inhibitors of HIV Reverse Transcriptase

Current HIV Research, 2006
Acquired immunodeficiency syndrome (AIDS), a degenerative disease of the immune and central nervous systems, is an enormous world-wide health threat. No cure has been found, and research is aimed at developing chemotherapy against the causative agent, human immunodeficiency virus (HIV).
openaire   +2 more sources

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

AIDS, 1999
To study the effect of the interruption of reverse transriptase inhibitor (RTI) therapy or a switch from RTI to protease inhibitors, on the genotypic drug-resistance pattern of plasma HIV-1.Nine patients who completely stopped all medication, and five patients who switched from a treatment with RTI to a regimen containing protease inhibitors only, were
C, Verhofstede, F V, Wanzeele, B, Van Der Gucht, N, De Cabooter, J, Plum   +4 more
openaire   +2 more sources

Rationale and Experience with Reverse Transcriptase Inhibitors and Protease Inhibitors

Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 1995
The majority of antiretroviral agents used in the treatment of HIV are targeted at the HIV reverse transcriptase (RT) enzyme. In a continuing effort to develop more effective antiviral regimens, drugs that target other specific enzymes in the virus replication cycle are under development. A promising new class of drugs is the protease inhibitors. These
openaire   +2 more sources